Activation of the Renin-Angiotensin System in Heart Failure

Heart Failure

Volumn , Issue , 2011, Pages 134-151

  Kumar, Rajesh ^a   Baker, Kenneth M ^a,b   Pan, Jing ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b Division of Molecular Cardiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863394190     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5895-3.10009-9     Document Type: Chapter

References (289)

1. Schmieder R.E., Hilgers K.F., Schlaich M.P., et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007, 369:1208-1219.
2. Steckelings U.M., Kaschina E., Unger T. The AT2 receptor-a matter of love and hate. Peptides 2005, 26:1401-1409.
3. Tigerstedt R., Bergman P. Niere und Kreislauf. Skand Arch Physiol 1898, 8:223-271.
4. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86:747-803.
5. Reudelhuber T.L., Bernstein K.E., Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension 2007, 49:1196-1201.
6. Carey R.M., Siragy H.M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003, 24:261-271.
7. Kumar R., Singh V.P., Baker K.M. The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab 2007, 18:208-214.
8. Nguyen G., Contrepas A. Physiology and pharmacology of the (pro)renin receptor. Curr Opin Pharmacol 2008, 8:127-132.
9. Lambert D.W., Hooper N.M., Turner A.J. Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol 2008, 75:781-786.
10. Danser A.H. Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003, 35:759-768.
11. Crowley S.D., Gurley S.B., Coffman T.M. AT(1) receptors and control of blood pressure: the kidney and more. Trends Cardiovasc Med 2007, 17:30-34.
12. Stec D.E., Davisson R.L., Haskell R.E., et al. Efficient liver-specific deletion of a floxed human angiotensinogen transgene by adenoviral delivery of Cre recombinase in vivo. J Biol Chem 1999, 274:21285-21290.
13. Gould A.B., Green D. Kinetics of the human renin and human substrate reaction. Cardiovasc Res 1971, 5:86-89.
14. Kim H.S., Krege J.H., Kluckman K.D., et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A 1995, 92:2735-2739.
15. Merrill D.C., Thompson M.W., Carney C.L., et al. Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J Clin Invest 1996, 97:1047-1055.
16. Campbell D.J., Bouhnik J., Coezy E., et al. Characterization of precursor and secreted forms of human angiotensinogen. J Clin Invest 1985, 75:1880-1893.
17. Brasier A.R., Han Y., Sherman C.T. Transcriptional regulation of angiotensinogen gene expression. Vitam Horm 1999, 57:217-247.
18. Clauser E., Gaillard I., Wei L., et al. Regulation of angiotensinogen gene. Am J Hypertens 1989, 2:403-410.
19. Herrmann H.C., Dzau V.J. The feedback regulation of angiotensinogen production by components of the renin-angiotensin system. Circ Res 1983, 52:328-334.
20. Lu H., Boustany-Kari C.M., Daugherty A., et al. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007, 292:E1280-E1287.
21. Satou R., Gonzalez-Villalobos R.A., Miyata K., et al. Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells. Am J Physiol Renal Physiol 2008, 295:F283-F289.
22. Dickson M.E., Sigmund C.D. Genetic basis of hypertension: revisiting angiotensinogen. Hypertension 2006, 48:14-20.
23. Nguyen G., Delarue F., Burckle C., et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417-1427.
24. Kang J.J., Toma I., Sipos A., et al. The collecting duct is the major source of prorenin in diabetes. Hypertension 2008, 51:1597-1604.
25. Sealey J.E., Glorioso N., Itskovitz J., et al. Ovarian prorenin. Clin Exp Hypertens A 1987, 9:1435-1454.
26. Hackenthal E., Paul M., Ganten D., et al. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 1990, 70:1067-1116.
27. Bader M., Ganten D. Regulation of renin: new evidence from cultured cells and genetically modified mice. J Mol Med 2000, 78:130-139.
28. Michaud A., Williams T.A., Chauvet M.T., et al. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Mol Pharmacol 1997, 51:1070-1076.
29. Largo R., Gomez-Garre D., Soto K., et al. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 1999, 33:732-739.
30. Fuchs S., Xiao H.D., Hubert C., et al. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 2008, 51:267-274.
31. Bernstein K.E., Xiao H.D., Frenzel K., et al. Six truisms concerning ACE and the renin-angiotensin system educed from the genetic analysis of mice. Circ Res 2005, 96:1135-1144.
32. Re R.N. Tissue renin angiotensin systems. Med Clin North Am 2004, 88:19-38.
33. van Kats J.P., Danser A.H.J., van Maegen J., et al. Angiotensin production in the heart: a quantitative study with use of radiolabelled angiotensin infusions. Circulation 1998, 98:73-81.
34. Dostal D.E., Baker K.M. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?. Circ Res 1999, 85:643-650.
35. Dell'Italia L.J., Meng Q.C., Balcells E., et al. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest 1997, 100:253-258.
36. Heller L.J., Opsahl J.A., Wernsing S.E., et al. Myocardial and plasma renin-angiotensinogen dynamics during pressure-induced cardiac hypertrophy. Am J Physiol 1998, 274:R849-R856.
37. Catanzaro D.F. Physiological relevance of renin/prorenin binding and uptake. Hypertens Res 2005, 28:97-105.
38. Muller D.N., Fischli W., Clozel J.P., et al. Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res 1998, 82:13-20.
39. Peters J. Secretory and cytosolic (pro)renin in kidney, heart, and adrenal gland. J Mol Med 2008, 86:711-714.
40. Peters J., Farrenkopf R., Clausmeyer S., et al. Functional significance of prorenin internalization in the rat heart. Circ Res 2002, 90:1135-1141.
41. Peters J., Clausmeyer S. Intracellular sorting of renin: cell type specific differences and their consequences. J Mol Cell Cardiol 2002, 34:1561-1568.
42. Zhang X., Dostal D.E., Reiss K., et al. Identification and activation of autocrine renin-angiotensin system in adult ventricular myocytes. Am J Physiol 1995, 269:H1791-H1802.
43. Sun Y., Zhang J., Zhang J.Q., et al. Renin expression at sites of repair in the infarcted rat heart. J Mol Cell Cardiol 2001, 33:995-1003.
44. Barlucchi L., Leri A., Dostal D.E., et al. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res 2001, 88:298-304.
45. Clausmeyer S., Reinecke A., Farrenkopf R., et al. Tissue-specific expression of a rat renin transcript lacking the coding sequence for the prefragment and its stimulation by myocardial infarction. Endocrinology 2000, 141:2963-2970.
46. Baker K.M., Chernin M.I., Wixson S.K., et al. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990, 259:H324-H332.
47. Hokimoto S., Yasue H., Fujimoto K., et al. Increased angiotensin converting enzyme activity in left ventricular aneurysm of patients after myocardial infarction. Cardiovasc Res 1995, 29:664-669.
48. Diez J., Panizo A., Hernandez M., et al. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension 1997, 30:1029-1034.
49. Dostal D.E., Rothblum K.N., Conrad K.M., et al. Detection of angiotensin I and II in cultured rat cardiac myocytes and fibroblasts. Am J Physiol 1992, 263:C851-C863.
50. Jahanyar J., Youker K.A., Loebe M., et al. Mast cell-derived cathepsin g: a possible role in the adverse remodeling of the failing human heart. J Surg Res 2007, 140:199-203.
51. Holycross B.J., Saye J., Harrison J.K., et al. Polymerase chain reaction analysis of renin in rat aortic smooth muscle. Hypertension 1992, 19:697-701.
52. Hu W.Y., Fukuda N., Satoh C., et al. Phenotypic modulation by fibronectin enhances the angiotensin II-generating system in cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000, 20:1500-1505.
53. Lavrentyev E.N., Estes A.M., Malik K.U. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res 2007, 101:455-464.
54. Balcells E., Meng Q.C., Johnson W.H., et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997, 273:H1769-H1774.
55. Wolny A., Clozel J.P., Rein J., et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997, 80:219-227.
56. Li P., Chen P.M., Wang S.W., et al. Time-dependent expression of chymase and angiotensin converting enzyme in the hamster heart under pressure overload. Hypertens Res 2002, 25:757-762.
57. Chen L.Y., Li P., He Q., et al. Transgenic study of the function of chymase in heart remodeling. J Hypertens 2002, 20:2047-2055.
58. McDonald J.E., Padmanabhan N., Petrie M.C., et al. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate (Pro(11)(D)-Ala(12)) angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans. Circulation 2001, 104:1805-1808.
59. Kokkonen J.O., Lindstedt K.A., Kovanen P.T. Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms?. Circulation 2003, 107:2522-2544.
60. Doggrell S.A., Wanstall J.C. Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Can J Physiol Pharmacol 2005, 83:123-130.
61. Baker, K.M., Chernin, M.I., Wixson, S.K., Aceto, J.F. (1990). Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol Heart Circ Physiol, 259, H324-H332.
62. Malhotra R., Sadoshima J., Brosius F.C., et al. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro. Circ Res 1999, 85:137-146.
63. Fukuzawa J., Booz G.W., Hunt R.A., et al. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. Hypertension 2000, 35:1191-1196.
64. Dostal D.E., Booz G.W., Baker K.M. Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and beta-adrenergic stimulation. Basic Res Cardiol 2000, 95:485-490.
65. Booz G.W., Baker K.M. Intracellular signaling and the cardiac renin angiotensin system 2004, John Wiley & Sons, West Sussex, UK.
66. Singh V.P., Le B., Bhat V.B., et al. High glucose induced regulation of intracellular angiotensin II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol 2007, 293:H939-H948.
67. Singh V.P., Baker K.M., Kumar R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol 2008, 294:H1675-H1684.
68. Frustaci A., Kajstura J., Chimenti C., et al. Myocardial cell death in human diabetes. Circ Res 2000, 87:1123-1132.
69. Booz G.W., Conrad K.M., Hess A.L., et al. Angiotensin-II-binding sites on hepatocyte nuclei. Endocrinology 1992, 130:3641-3649.
70. Re R.N., Vizard D.L., Brown J., et al. Angiotensin II receptors in chromatin fragments generated by micrococcal nuclease. Biochem Biophys Res Commun 1984, 119:220-227.
71. Tang S.S., Rogg H., Schumacher R., et al. Characterization of nuclear angiotensin-II-binding sites in rat liver and comparison with plasma membrane receptors. Endocrinology 1992, 131:374-380.
72. 1 receptors and angiotensin II within the kidney of the male congenic mRen2.Lewis rat. Am J Physiol Renal Physiol 2006, 290:F1497-F1506.
73. Eggena P., Zhu J.H., Clegg K., et al. Nuclear angiotensin receptors induce transcription of renin and angiotensinogen mRNA. Hypertension 1993, 22:496-501.
74. Re R.N. The intracellular renin angiotensin system: the tip of the intracrine physiology iceberg. Am J Physiol Heart Circ Physiol 2007, 293:H905-H906.
75. Baker K.M., Chernin M.I., Schreiber T., et al. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept 2004, 120:5-13.
76. Haller H., Lindschau C., Erdmann B., et al. Effects of intracellular angiotensin II in vascular smooth muscle cells. Circ Res 1996, 79:765-772.
77. 1 receptor. Am J Physiol Cell Physiol 2006, 291:C995-C1001.
78. Kumar R., Singh V.P., Baker K.M. The intracellular renin-angiotensin system-implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens 2008, 17:168-173.
79. 2 receptors in the mouse heart. Hypertension 2005, 46:937-942.
80. Kostenis E., Milligan G., Christopoulos A., et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005, 111:1806-1813.
81. Averill D.B., Ishiyama Y., Chappell M.C., et al. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 2003, 108:2141-2146.
82. Wei C.C., Ferrario C.M., Brosnihan K.B., et al. Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo. J Pharmacol Exp Ther 2002, 300:324-329.
83. Loot A.E., Roks A.J., Henning R.H., et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002, 105:1548-1550.
84. Zisman L.S., Keller R.S., Weaver B., et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 2003, 108:1707-1712.
85. Crackower M.A., Sarao R., Oudit G.Y., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822-828.
86. Der Sarkissian S., Grobe J.L., Yuan L., et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008, 51:712-718.
87. Donoghue M., Wakimoto H., Maguire C.T., et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 2003, 35:1043-1053.
88. Trask A.J., Averill D.B., Ganten D., et al. Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol Heart Circ Physiol 2007, 292:H3019-H3024.
89. Oudit G.Y., Kassiri Z., Patel M.P., et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007, 75:29-39.
90. Hernandez Prada J.A., Ferreira A.J., Katovich M.J., et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008, 51:1312-1317.
91. Reaux A., Fournie-Zaluski M.C., Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 2001, 12:157-162.
92. 2 receptor-mediated natriuresis in rats. Hypertension 2008, 51:460-465.
93. Bodineau L., Frugiere A., Marc Y., et al. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 2008, 51:1318-1325.
94. Ruiz-Ortega M., Esteban V., Egido J. The regulation of the inflammatory response through nuclear factor-kappaB pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovasc Med 2007, 17:19-25.
95. Albiston A.L., McDowall S.G., Matsacos D., et al. Evidence that the angiotensin IV (AT[4]) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001, 276:48623-48626.
96. Wallis M.G., Lankford M.F., Keller S.R. Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP. Am J Physiol Endocrinol Metab 2007, 293:E1092-E1102.
97. Esteban V., Ruperez M., Sanchez-Lopez E., et al. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res 2005, 96:965-973.
98. Franken A.A., Derkx F.H., Man in't Veld A.J., et al. High plasma prorenin in diabetes mellitus and its correlation with some complications. J Clin Endocrinol Metab 1990, 71:1008-1015.
99. Nguyen G. Renin/prorenin receptors. Kidney Int 2006, 69:1503-1506.
100. Saris J.J., 'tHoen P.A., Garrelds I.M., et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006, 48:564-571.
101. Nguyen G., Delarue F., Berrou J., et al. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996, 50:1897-1903.
102. Huang Y., Noble N.A., Zhang J., et al. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007, 72:45-52.
103. Sakoda M., Ichihara A., Kaneshiro Y., et al. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007, 30:1139-1146.
104. Veniant M., Menard J., Bruneval P., et al. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996, 98:1966-1970.
105. Campbell D.J. Critical review of prorenin and (pro)renin receptor research. Hypertension 2008, 51:1259-1264.
106. Cohn J.N. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Adv Ther 2007, 24:1290-1304.
107. Marchesi C., Paradis P., Schiffrin E.L. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008, 29:367-374.
108. Unger T., Jakobsen A., Heroys J., et al. Targeting cardiovascular protection: the concept of dual renin-angiotensin system control. Medscape J Med 2008, 10(suppl):S4.
109. Murphy T.J., Alexander R.W., Griendling K.K., et al. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991, 351:233-236.
110. Nakajima M., Mukoyama M., Pratt R.E., et al. Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem Biophys Res Commun 1993, 197:393-399.
111. Horiuchi M., Akishita M., Dzau V.J. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999, 33:613-621.
112. Dinh D.T., Frauman A.G., Johnston C.I., et al. Angiotensin receptors: distribution, signalling and function. Clin Sci (Lond) 2001, 100:481-492.
113. Sasaki K., Yamano Y., Bardhan S., et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991, 351:230-233.
114. Iwai N., Inagami T. Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett 1992, 298:257-260.
115. Guo D.F., Furuta H., Mizukoshi M., et al. The genomic organization of human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1994, 200:313-319.
116. 1 receptor. J Biol Chem 1994, 269:30953-30959.
117. Timmermans P.B., Wong P.C., Chiu A.T., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45:205-251.
118. 1A) 3-untranslated region in determining cellular responses to agonist: evidence for recognition by RNA binding proteins. Biochem J 1998, 329(pt 2):255-264.
119. Hunyady L., Catt K.J., Clark A.J., et al. Mechanisms and functions of AT(1) angiotensin receptor internalization. Regul Pept 2000, 91:29-44.
120. 1A) receptor carboxyl terminus: a role in receptor endocytosis. Mol Endocrinol 1998, 12:1513-1524.
121. Ribas C., Penela P., Murga C., et al. The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta 2007, 1768:913-922.
122. de Gasparo M., Husain A., Alexander W., et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995, 25:924-927.
123. Koike G., Horiuchi M., Yamada T., et al. Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung. Biochem Biophys Res Commun 1994, 203:1842-1850.
124. Mukoyama M., Nakajima M., Horiuchi M., et al. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993, 268:24539-24542.
125. 2 angiotensin receptors. FEBS Lett 2006, 580:41-45.
126. 2 receptor in hypertension. Am J Hypertens 2000, 13:62S-67S.
127. 2 receptor in postinfarction left ventricular remodeling. Hypertension 2003, 41:814-818.
128. 1 receptor antagonist in post-myocardial infarction remodeling. Life Sci 2006, 80:82-88.
129. 2 receptors in neointimal formation. Circulation 2002, 106:847-853.
130. Schneider M.D., Lorell B.H. AT(2), judgment day: which angiotensin receptor is the culprit in cardiac hypertrophy?. Circulation 2001, 104:247-248.
131. Yang Z., Bove C.M., French B.A., et al. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 2002, 106:106-111.
132. 2 receptors in ventricular myocytes. Am J Physiol Heart Circ Physiol 2008, 294:H1274-H1281.
133. 2 receptor knockout mice. Acta Physiol Scand 2004, 181:487-494.
134. 4 receptors: specificity and distribution. Kidney Int 1994, 46:1510-1512.
135. Swanson G.N., Hanesworth J.M., Sardinia M.F., et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 1992, 40:409-419.
136. 4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement. Trends Endocrinol Metab 2003, 14:72-77.
137. 4 system in mediating natriuresis in the rat. Peptides 2001, 22:935-944.
138. Kramar E.A., Krishnan R., Harding J.W., et al. Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. Regul Pept 1998, 74:185-192.
139. Chen S., Patel J.M., Block E.R. Angiotensin IV-mediated pulmonary artery vasorelaxation is due to endothelial intracellular calcium release. Am J Physiol Lung Cell Mol Physiol 2000, 279:L849-L856.
140. Patel J.M., Martens J.R., Li Y.D., et al. Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation. Am J Physiol 1998, 275:L1061-L1068.
141. Li Y.D., Block E.R., Patel J.M. Activation of multiple signaling modules is critical in angiotensin IV-induced lung endothelial cell proliferation. Am J Physiol Lung Cell Mol Physiol 2002, 283:L707-L716.
142. Mehta J.L., Li D.Y., Yang H., et al. Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells. J Cardiovasc Pharmacol 2002, 39:789-794.
143. Wang L., Eberhard M., Erne P. Stimulation of DNA and RNA synthesis in cultured rabbit cardiac fibroblasts by angiotensin IV. Clin Sci (Lond) 1995, 88:557-562.
144. 4 receptor agonist (Nle1)-angiotensin IV reduces mechanically induced immediate-early gene expression in the isolated rabbit heart. Regul Pept 1997, 71:175-183.
145. Slinker B.K., Wu Y., Brennan A.J., et al. Angiotensin IV has mixed effects on left ventricle systolic function and speeds relaxation. Cardiovasc Res 1999, 42:660-669.
146. Griendling K.K., Ushio-Fukai M., Lassegue B., et al. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997, 29:366-373.
147. 2 receptors. Blood Press Suppl 1996, 2:41-46.
148. Ruan X., Arendshorst W.J. Role of protein kinase C in angiotensin II-induced renal vasoconstriction in genetically hypertensive rats. Am J Physiol 1996, 270:F945-F952.
149. 2+ in angiotensin II-induced mitogenesis of cardiac fibroblasts. Am J Physiol 1994, 267:C1308-C1318.
150. Touyz R.M., Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res 2002, 35:1001-1015.
151. Anand-Srivastava M.B. Angiotensin II receptors negatively coupled to adenylate cyclase in rat aorta. Biochem Biophys Res Commun 1983, 117:420-428.
152. Kem D.C., Johnson E.I., Capponi A.M., et al. Effect of angiotensin II on cytosolic free calcium in neonatal rat cardiomyocytes. Am J Physiol 1991, 261:C77-C85.
153. 1 calcium signaling in renal vascular smooth muscle cells. J Am Soc Nephrol 1999, 10(suppl. 11):S84-S89.
154. 2+ channels in rat portal vein myocytes. J Biol Chem 1997, 272:23180-23185.
155. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000, 52:11-34.
156. Yin G., Yan C., Berk B.C. Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol 2003, 35:780-783.
157. Haendeler J., Berk B.C. Angiotensin II mediated signal transduction. Important role of tyrosine kinases. Regul Pept 2000, 95:1-7.
158. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007, 292:C82-C97.
159. Delcourt N., Bockaert J., Marin P. GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol Sci 2007, 28:602-607.
160. Natarajan K., Berk B.C. Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases. Methods Mol Biol 2006, 332:51-77.
161. Saito Y., Berk B.C. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol 2001, 33:3-7.
162. Zwick E., Bange J., Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002, 8:17-23.
163. Eguchi S., Dempsey P.J., Frank G.D., et al. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001, 276:7957-7962.
164. Mifune M., Ohtsu H., Suzuki H., et al. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 2005, 280:26592-26599.
165. Suzuki H., Motley E.D., Frank G.D., et al. Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. Curr Med Chem Cardiovasc Hematol Agents 2005, 3:305-322.
166. Eguchi S., Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul Pept 2000, 91:13-20.
167. Shah B.H., Catt K.J. A central role of EGF receptor transactivation in angiotensin II-induced cardiac hypertrophy. Trends Pharmacol Sci 2003, 24:239-244.
168. Zahradka P., Litchie B., Storie B., et al. Transactivation of the insulin-like growth factor-I receptor by angiotensin II mediates downstream signaling from the angiotensin II type 1 receptor to phosphatidylinositol 3-kinase. Endocrinology 2004, 145:2978-2987.
169. Azar Z.M., Mehdi M.Z., Srivastava A.K. Insulin-like growth factor type-1 receptor transactivation in vasoactive peptide and oxidant-induced signaling pathways in vascular smooth muscle cells. Can J Physiol Pharmacol 2007, 85:105-111.
170. Saito S., Frank G.D., Mifune M., et al. Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-delta and c-Src. J Biol Chem 2002, 277:44695-44700.
171. Kelly D.J., Cox A.J., Gow R.M., et al. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 2004, 44:195-202.
172. Kim S., Zhan Y., Izumi Y., et al. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol 2000, 20:2539-2545.
173. Wang C., Wu L.L., Liu J., et al. Crosstalk between angiotensin II and platelet derived growth factor-BB mediated signal pathways in cardiomyocytes. Chin Med J (Engl) 2008, 121:236-240.
174. Godeny M.D., Sayeski P.P. ANG II-induced cell proliferation is dually mediated by c-Src/Yes/Fyn-regulated ERK1/2 activation in the cytoplasm and PKCzeta-controlled ERK1/2 activity within the nucleus. Am J Physiol Cell Physiol 2006, 291:C1297-C1307.
175. Touyz R.M., He G., Wu X.H., et al. Src is an important mediator of extracellular signal-regulated kinase 1/2-dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients. Hypertension 2001, 38:56-64.
176. Tatosyan A.G., Mizenina O.A. Kinases of the Src family: structure and functions. Biochemistry (Mosc) 2000, 65:49-58.
177. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997, 13:513-609.
178. Erpel T., Courtneidge S.A. Src family protein tyrosine kinases and cellular signal transduction pathways. Curr Opin Cell Biol 1995, 7:176-182.
179. Parsons J.T. Focal adhesion kinase: the first ten years. J Cell Sci 2003, 116:1409-1416.
180. Rocic P., Griffin T.M., McRae C.N., et al. Altered PYK2 phosphorylation by ANG II in hypertensive vascular smooth muscle. Am J Physiol Heart Circ Physiol 2002, 282:H457-H465.
181. Qin J., Liu Z.X. FAK-related nonkinase attenuates hypertrophy induced by angiotensin-II in cultured neonatal rat cardiac myocytes. Acta Pharmacol Sin 2006, 27:1159-1164.
182. Govindarajan G., Eble D.M., Lucchesi P.A., et al. Focal adhesion kinase is involved in angiotensin II-mediated protein synthesis in cultured vascular smooth muscle cells. Circ Res 2000, 87:710-716.
183. Rocic P., Govindarajan G., Sabri A., et al. A role for PYK2 in regulation of ERK1/2 MAP kinases and PI 3-kinase by ANG II in vascular smooth muscle. Am J Physiol Cell Physiol 2001, 280:C90-C99.
184. Guan J.L. Role of focal adhesion kinase in integrin signaling. Int J Biochem Cell Biol 1997, 29:1085-1096.
185. Sabri A., Govindarajan G., Griffin T.M., et al. Calcium- and protein kinase C-dependent activation of the tyrosine kinase PYK2 by angiotensin II in vascular smooth muscle. Circ Res 1998, 83:841-851.
186. Matsuda M., Mayer B.J., Fukui Y., et al. Binding of transforming protein, P47gag-crk, to a broad range of phosphotyrosine-containing proteins. Science 1990, 248:1537-1539.
187. Defilippi P., Di Stefano P., Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 2006, 16:257-263.
188. O'Neill G.M., Fashena S.J., Golemis E.A. Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol 2000, 10:111-119.
189. Takahashi T., Kawahara Y., Taniguchi T., et al. Tyrosine phosphorylation and association of p130Cas and c-Crk II by ANG II in vascular smooth muscle cells. Am J Physiol 1998, 274:H1059-H1065.
190. Kyaw M., Yoshizumi M., Tsuchiya K., et al. Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase activation. Mol Pharmacol 2004, 65:832-841.
191. Schindler C., Levy D.E., Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007, 282:20059-20063.
192. Murray P.J. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178:2623-2629.
193. Aaronson D.S., Horvath C.M. A road map for those who don't know JAK-STAT. Science 2002, 296:1653-1655.
194. Booz G.W., Day J.N., Baker K.M. Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 2002, 34:1443-1453.
195. Bolli R., Dawn B., Xuan Y.T. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 2003, 13:72-79.
196. Mascareno E., Siddiqui M.A. The role of JAK/STAT signaling in heart tissue renin-angiotensin system. Mol Cell Biochem 2000, 212:171-175.
197. El-Adawi H., Deng L., Tramontano A., et al. The functional role of the JAK-STAT pathway in post-infarction remodeling. Cardiovasc Res 2003, 57:129-138.
198. Mascareno E., El-Shafei M., Maulik N., et al. JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation 2001, 104:325-329.
199. Banes-Berceli A.K., Ketsawatsomkron P., Ogbi S., et al. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol 2007, 293:H1291-H1299.
200. Prasad S.V., Perrino C., Rockman H.A. Role of phosphoinositide 3-kinase in cardiac function and heart failure. Trends Cardiovasc Med 2003, 13:206-212.
201. Saward L., Zahradka P. Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ Res 1997, 81:249-257.
202. Oudit G.Y., Sun H., Kerfant B.G., et al. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004, 37:449-471.
203. Walker E.H., Perisic O., Ried C., et al. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999, 402:313-320.
204. Fruman D.A., Meyers R.E., Cantley L.C. Phosphoinositide kinases. Annu Rev Biochem 1998, 67:481-507.
205. McMullen J.R., Shioi T., Zhang L., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 2003, 100:12355-12360.
206. Alloatti G., Montrucchio G., Lembo G., et al. Phosphoinositide 3-kinase gamma: kinase-dependent and -independent activities in cardiovascular function and disease. Biochem Soc Trans 2004, 32:383-386.
207. Kerfant B.G., Rose R.A., Sun H., et al. Phosphoinositide 3-kinase gamma regulates cardiac contractility by locally controlling cyclic adenosine monophosphate levels. Trends Cardiovasc Med 2006, 16:250-256.
208. El Mabrouk M., Touyz R.M., Schiffrin E.L. Differential ANG II-induced growth activation pathways in mesenteric artery smooth muscle cells from SHR. Am J Physiol Heart Circ Physiol 2001, 281:H30-H39.
209. Chen Q.M., Tu V.C., Purdon S., et al. Molecular mechanisms of cardiac hypertrophy induced by toxicants. Cardiovasc Toxicol 2001, 1:267-283.
210. Pimienta G., Pascual J. Canonical and alternative MAPK signaling. Cell Cycle 2007, 6:2628-2632.
211. Strniskova M., Barancik M., Ravingerova T. Mitogen-activated protein kinases and their role in regulation of cellular processes. Gen Physiol Biophys 2002, 21:231-255.
212. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
213. Kim S., Iwao H. Activation of mitogen-activated protein kinases in cardiovascular hypertrophy and remodeling. Jpn J Pharmacol 1999, 80:97-102.
214. Ravingerova T., Barancik M., Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 2003, 247:127-138.
215. Wei S.G., Yu Y., Zhang Z.H., et al. Angiotensin II-triggered p44/42 mitogen-activated protein kinase mediates sympathetic excitation in heart failure rats. Hypertension, 342-350 2008.
216. Kim S., Iwao H. Stress and vascular responses: mitogen-activated protein kinases and activator protein-1 as promising therapeutic targets of vascular remodeling. J Pharmacol Sci 2003, 91:177-181.
217. Wang Y., Su B., Sah V.P., et al. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 1998, 273:5423-5426.
218. Schmitz U., Ishida T., Ishida M., et al. Angiotensin II stimulates p21-activated kinase in vascular smooth muscle cells: role in activation of JNK. Circ Res 1998, 82:1272-1278.
219. Wang Y., Huang S., Sah V.P., et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998, 273:2161-2168.
220. Hayashida W., Kihara Y., Yasaka A., et al. Stage-specific differential activation of mitogen-activated protein kinases in hypertrophied and failing rat hearts. J Mol Cell Cardiol 2001, 33:733-744.
221. Haq S., Choukroun G., Lim H., et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001, 103:670-677.
222. Liao P., Georgakopoulos D., Kovacs A., et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A 2001, 98:12283-12288.
223. Liu Y.H., Wang D., Rhaleb N.E., et al. Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. J Card Fail 2005, 11:74-81.
224. Pellieux C., Sauthier T., Aubert J.F., et al. Angiotensin II-induced cardiac hypertrophy is associated with different mitogen-activated protein kinase activation in normotensive and hypertensive mice. J Hypertens 2000, 18:1307-1317.
225. Lezoualc'h F., Metrich M., Hmitou I., et al. Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol 2008, 44:623-632.
226. Clerk A., Sugden P.H. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ Res 2000, 86:1019-1023.
227. Bhattacharya M., Babwah A.V., Ferguson S.S. Small GTP-binding protein-coupled receptors. Biochem Soc Trans 2004, 32:1040-1044.
228. Vahebi S., Solaro R.J. Cardiac sarcomeric function, small G-protein signaling, and heart failure. Panminerva Med 2005, 47:133-142.
229. Ruan H., Mitchell S., Vainoriene M., et al. Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy. Circulation 2007, 116:596-605.
230. Sadoshima J., Izumo S. The heterotrimeric G q protein-coupled angiotensin II receptor activates p21 ras via the tyrosine kinase-Shc-Grb2-Sos pathway in cardiac myocytes. EMBO J 1996, 15:775-787.
231. Yamakawa T., Tanaka S., Numaguchi K., et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 2000, 35:313-318.
232. Jalil J., Lavandero S., Chiong M., et al. Rho/Rho kinase signal transduction pathway in cardiovascular disease and cardiovascular remodeling. Rev Esp Cardiol 2005, 58:951-961.
233. Aikawa R., Komuro I., Nagai R., et al. Rho plays an important role in angiotensin II-induced hypertrophic responses in cardiac myocytes. Mol Cell Biochem 2000, 212:177-182.
234. Choudhary S., Lu M., Cui R., et al. Involvement of a novel Rac/RhoA guanosine triphosphatase-nuclear factor-kappaB inducing kinase signaling pathway mediating angiotensin II-induced RelA transactivation. Mol Endocrinol 2007, 21:2203-2217.
235. Cui R., Tieu B., Recinos A., et al. RhoA mediates angiotensin II-induced phospho-Ser536 nuclear factor kappaB/RelA subunit exchange on the interleukin-6 promoter in VSMCs. Circ Res 2006, 99:723-730.
236. Laufs U., Liao J.K. Targeting Rho in cardiovascular disease. Circ Res 2000, 87:526-528.
237. Satoh M., Ogita H., Takeshita K., et al. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A 2006, 103:7432-7437.
238. Tsai C.T., Lai L.P., Kuo K.T., et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008, 117:344-355.
239. Gregg D., Rauscher F.M., Goldschmidt-Clermont P.J. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Am J Physiol Cell Physiol 2003, 285:C723-C734.
240. Harrison D.G., Cai H., Landmesser U., et al. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003, 4:51-61.
241. Nakagami H., Takemoto M., Liao J.K. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2003, 35:851-859.
242. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501.
243. Griendling K.K., Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 2000, 91:21-27.
244. Zhang M., Shah A.M. Role of reactive oxygen species in myocardial remodeling. Curr Heart Fail Rep 2007, 4:26-30.
245. Seddon M., Looi Y.H., Shah A.M. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007, 93:903-907.
246. Hanna I.R., Taniyama Y., Szocs K., et al. NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 2002, 4:899-914.
247. Cai H., Griendling K.K., Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003, 24:471-478.
248. Heymes C., Bendall J.K., Ratajczak P., et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003, 41:2164-2171.
249. Li J.M., Shah A.M. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 2003, 278:12094-12100.
250. Touyz R.M., Chen X., Tabet F., et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002, 90:1205-1213.
251. Landmesser U., Cai H., Dikalov S., et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40:511-515.
252. Tsutsui H., Ide T., Kinugawa S. Mitochondrial oxidative stress, DNA damage, and heart failure. Antioxid Redox Signal 2006, 8:1737-1744.
253. Sawyer D.B., Colucci W.S. Mitochondrial oxidative stress in heart failure: "oxygen wastage" revisited. Circ Res 2000, 86:119-120.
254. Ikeuchi M., Matsusaka H., Kang D., et al. Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. Circulation 2005, 112:683-690.
255. Ricci C., Pastukh V., Leonard J., et al. Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis. Am J Physiol Cell Physiol 2008, 294:C413-C422.
256. Doughan A.K., Harrison D.G., Dikalov S.I. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008, 102:488-496.
257. Kimura S., Zhang G.X., Nishiyama A., et al. Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension 2005, 45:438-444.
258. Cappola T.P., Kass D.A., Nelson G.S., et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001, 104:2407-2411.
259. Landmesser U., Spiekermann S., Dikalov S., et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002, 106:3073-3078.
260. Engberding N., Spiekermann S., Schaefer A., et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation 2004, 110:2175-2179.
261. Minhas K.M., Saraiva R.M., Schuleri K.H., et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 2006, 98:271-279.
262. Landmesser U., Spiekermann S., Preuss C., et al. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 2007, 27:943-948.
263. 2 receptor. Trends Endocrinol Metab 2000, 11:1-6.
264. + currents involves an inhibitory GTP binding protein. Am J Physiol 1994, 267:C1389-C1397.
265. 2 receptor selectively associates with Gialpha2 and Gialpha3 in the rat fetus. J Biol Chem 1996, 271:15026-15033.
266. Huang X.C., Richards E.M., Sumners C. Angiotensin II type 2 receptor-mediated stimulation of protein phosphatase 2A in rat hypothalamic/brainstem neuronal cocultures. J Neurochem 1995, 65:2131-2137.
267. Huang X.C., Sumners C., Richards E.M. Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion. Adv Exp Med Biol 1996, 396:209-215.
268. 2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Commun 1992, 183:206-211.
269. 1 receptor-mediated pressor and chronotropic effects. J Clin Invest 1998, 101:527-535.
270. 2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. J Clin Invest 1999, 103:63-71.
271. 1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A 1995, 92:10663-10667.
272. 2 receptors, regulates STAT activation by negative crosstalk. Circ Res 1999, 84:876-882.
273. Searles C.D., Harrison D.G. The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice. J Clin Invest 1999, 104:1013-1014.
274. Moore A.F., Heiderstadt N.T., Huang E., et al. Selective inhibition of the renal angiotensin type 2 receptor increases blood pressure in conscious rats. Hypertension 2001, 37:1285-1291.
275. Bartunek J., Weinberg E.O., Tajima M., et al. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation 1999, 99:22-25.
276. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998, 31:349-355.
277. 2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertens 2006, 24:2417-2422.
278. Jiao H., Cui X.L., Torti M., et al. Arachidonic acid mediates angiotensin II effects on p21ras in renal proximal tubular cells via the tyrosine kinase-Shc-Grb2-Sos pathway. Proc Natl Acad Sci U S A 1998, 95:7417-7421.
279. Dulin N.O., Alexander L.D., Harwalkar S., et al. Phospholipase A2-mediated activation of mitogen-activated protein kinase by angiotensin II. Proc Natl Acad Sci U S A 1998, 95:8098-8102.
280. - symport through a phosphoinositide-independent mechanism in cardiac cells. J Biol Chem 1995, 270:20432-20438.
281. Hannun Y.A., Bell R.M. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 1989, 243:500-507.
282. Lehtonen J.Y., Horiuchi M., Daviet L., et al. Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. J Biol Chem 1999, 274:16901-16906.
283. 2 receptor stimulation induces generation of ceramides in PC12W cells. FEBS Lett 1999, 443:75-79.
284. Wang J., Zhen L., Klug M.G., et al. Involvement of caspase 3- and 8-like proteases in ceramide-induced apoptosis of cardiomyocytes. J Card Fail 2000, 6:243-249.
285. Gulbins E. Regulation of death receptor signaling and apoptosis by ceramide. Pharmacol Res 2003, 47:393-399.
286. Schutze S., Potthoff K., Machleidt T., et al. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 1992, 71:765-776.
287. Johns D.G., Osborn H., Webb R.C. Ceramide: a novel cell signaling mechanism for vasodilation. Biochem Biophys Res Commun 1997, 237:95-97.
288. Johns D.G., Webb R.C., Charpie J.R. Impaired ceramide signalling in spontaneously hypertensive rat vascular smooth muscle: a possible mechanism for augmented cell proliferation. J Hypertens 2001, 19:63-70.
289. Charles R., Sandirasegarane L., Yun J., et al. Ceramide-coated balloon catheters limit neointimal hyperplasia after stretch injury in carotid arteries. Circ Res 2000, 87:282-288.